NCT07103642View on ClinicalTrials.gov

EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

CompletedOBSERVATIONAL
Enrollment

3,402

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

October 18, 2024

Study Completion Date

October 18, 2024

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

BGF

BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL

Trial Locations (1)

19803

AstraZeneca, Wilmington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT07103642 - EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study) | Biotech Hunter | Biotech Hunter